IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

J&J prostate cancer drug shrinks tumors in trial

Johnson and Johnson reported that its experimental oral prostate cancer drug shrank tumors and reduced PSA levels in an early-stage trial. The treatment showed promising results for patients with advanced disease.

Xurve View
Insights:
A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023. REUTERS/Brendan McDermid

Johnson & Johnson announced on Saturday morning that its oral prostate cancer drug shrank or eliminated tumors in 75% of evaluable patients during an early-stage trial.
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.